Home/Pipeline/SC0191

SC0191

Ovarian Cancer

Phase 1/2FDA trial approval (2023)

Key Facts

Indication

Ovarian Cancer

Phase

Phase 1/2

Status

FDA trial approval (2023)

Company

BioCity Biopharma

About BioCity Biopharma

A clinical-stage biopharma developing novel BIC/FIC therapeutics for oncology and nephrology, with a multi-modality pipeline and global clinical operations.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Ovarian Cancer Drugs

Drug	Company	Phase	Status
EXO‑Ovarian Cancer Test	INOVIQ	Phase 2/3	Active
CAR‑iNK‑OvCa	Cartherics	Preclinical	Active
MagSense™ FR Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Yondelis (trabectedin)	PharmaMar	Approved	Commercial/Lifecycle
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
NP-G2-044 + Chemotherapy Agents	Novita Pharmaceuticals	Phase 2a	Active (combination strategy)
Ivospemin (SBP-101)	Panbela Therapeutics	Phase 2	Active
Ovarian Cancer Early Detection Assay	GenEndeavor	Pre-clinical	Active
INVAC-1	Invectys	Phase 2	Active
Folate Receptor-Targeted PCC	Indi Molecular	Preclinical	Active
Immunomodulator Platform	OmniCyte	Pre-clinical	Active
Platform Candidate	FLAG Therapeutics	Preclinical	Active